&lt;p&gt;Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis&lt;/p&gt;

Deng, Shu; Lin, Shenyun; Shen, Jianping; Zeng, Yuqing

doi:10.2147/ott.s189825

Cited by 35 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, CHOP (cyclophosphamide, hydroxydaunorubicin (doxorubicin), (onco)vincristine and prednisolone) chemotherapy is most frequently used for the upfront treatment of ALCL based on experience with this regimen from high‐grade B‐cell lymphoma, despite poorer outcomes in the T‐cell lymphoma setting 72 . There is conflicting evidence as to whether the addition of etoposide leads to improved outcomes 73–77 …”

Section: Clinical Presentation and Investigationmentioning

confidence: 99%

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

et al. 2020

View full text Add to dashboard Cite

Summary Breast implant‐associated anaplastic large cell lymphoma (BIA‐ALCL) is an uncommon T‐cell non‐Hodgkin Lymphoma (NHL) associated with breast implants. Raising awareness of the possibility of BIA‐ALCL in anyone with breast implants and new breast symptoms is crucial to early diagnosis. The tumour begins on the inner aspect of the peri‐implant capsule causing an effusion, or less commonly a tissue mass to form within the capsule, which may spread locally or to more distant sites in the body. Diagnosis is usually made by cytological, immunohistochemical and immunophenotypic evaluation of the aspirated peri‐implant fluid: pleomorphic lymphocytes are characteristically anaplastic lymphoma kinase (ALK)‐negative and strongly positive for CD30. BIA‐ALCL is indolent in most patients but can progress rapidly. Surgical removal of the implant with the intact surrounding capsule (total en‐bloc capsulectomy) is usually curative. Late diagnosis may require more radical surgery and systemic therapies and although these are usually successful, poor outcomes and deaths have been reported. By adopting a structured approach, as suggested in these guidelines, early diagnosis and successful treatment will minimise the need for systemic treatments, reduce morbidity and the risk of poor outcomes.

show abstract

Section: Clinical Presentation and Investigationmentioning

confidence: 99%

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Wherever radiation therapy is being utilised for treatment of lymphoma, hypofractionation can be used in accordance with ILROG recommendations [45]. In patients with high grade T cell lymphoma requiring therapy, CHOP over CHOEP can be used given the lack of proven survival advantage of the latter [46].…”

Section: Lymphoma and Myelomamentioning

confidence: 99%

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

Singh

Dhawan

Jindal

et al. 2020

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

The current pandemic coronavirus, SARS-CoV-2, is known to cause severe infection (COVID-19) in patients with comorbidities, particularly cancer or an immunosuppressed state. Most healthcare systems in the country are likely to be overwhelmed soon if the pandemic moves to a stage of community transmission. Currently, limited evidence is available for managing patients with hematological disorders during the COVID-19 pandemic. The current review summarises the possible challenges clinicians are likely to face, key considerations to guide decision making, and possible solutions to the anticipated challenges. Disease specific recommendations and possible guidance for decision making have been suggested for most hematologic diseases that are feasible in our health setup. It is not meant to replace individual clinical judgment, but to provide a template to formulate local policies.

show abstract

“…T-cell malignancies commonly consist of two categories, T-cell acute lymphoblastic leukemia (T-ALL) and T-cell non-Hodgkin lymphoma (T-NHL), both of which have similar clinical therapies and poor prognosis [ 6 ]. Due to the varied morphology of subtypes and being highly heterogeneous, the diagnosis and treatment of this disease have become a great challenge [ 7 ]. Although the standard first-line treatment of T-cell malignancies is a CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone), which is still the representative chemotherapy [ 8 ], most patients still have a poor prognosis with an ORR of 65.8% because of rapid relapse [ 8 ].…”

Section: Introductionmentioning

confidence: 99%

One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence

Qing

Zhao

et al. 2021

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

T-cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug-induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well-known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T-cell malignancies with nonlethal concentration. Transcription activity of senescence-suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin-induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin-induced aging process. Results showed that wogonin increased the activity of senescence-associated β-galactosidase (SA-β-Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL-2 in senescent T-cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL-2 inhibitor Navitoclax (ABT-263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin-induced senescent cells. Thus, the “one-two punch” approach increased the sensibility of T-cell malignancies with low expression of BCL-2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T-cell malignancies.

show abstract

<p>Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis</p>

Cited by 35 publications

References 25 publications

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group

How to Use a Prioritised Approach for Treating Hematological Disorders During the COVID-19 Pandemic in India?

One‐Two Punch Therapy for the Treatment of T‐Cell Malignancies Involving p53‐Dependent Cellular Senescence

Contact Info

Product

Resources

About